SLDB Q1 2021 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$581M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M100.0% margin

Operating Income

-$17M-506.3% margin

Net Income

-$17M-506.7% margin

EPS (Diluted)

$-2.85

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$285M

Total Liabilities

$32M

Stockholders' Equity

$253M

Cash & Equivalents

$268M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$17M	-$27M	+37.1%
Net Income	-$17M	-$27M	+36.7%